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Preterm birth is the leading cause of perinatal morbidity and mortality, especially among 
neonates born less than 32 weeks’ gestation. Magnesium sulfate is the standard treatment 
for seizure prevention in preeclampsia and for fetal neuroprotection in mothers at risk for 
preterm delivery. However, the consequences of antenatal magnesium exposure on the 
very preterm neonate’s gastrointestinal tract are not fully established. This study will 
determine whether elevated magnesium levels in very preterm neonates are 
associated with adverse gastrointestinal outcomes from birth to 4 months. 
Specifically, using a prospective cohort design, we will measure magnesium in umbilical 
cord blood of very preterm neonates at the time of delivery and determine whether 
elevated levels are associated with feeding intolerance, necrotizing enterocolitis, or 
spontaneous intestinal perforation. This study may provide evidence for the use of 
umbilical cord magnesium concentration as a screening tool for risk for adverse 
gastrointestinal outcomes among very preterm neonates.  
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CHAPTER 1: INTRODUCTION 
1.1 Background  
1.1.1 Problem of Prematurity 
 
 Preterm birth is common, comprising 10.02% of live births in the United States in 
2018.1 With improvements in neonatal intensive care over the last three decades such as 
the use of antenatal corticosteroids and antibiotics, human viability is now approximately 
22-24 weeks’ gestation in high-income, developed countries.2,3 Despite these advances in 
neonatal care, preterm birth is still the leading cause of perinatal morbidity and mortality 
among non-anomalous newborns in the United States.4 Per a secondary analysis of 
115,502 neonates born from 2008-2011, very preterm neonates have a 7.34% risk of 
mortality with a 28.14% risk of developing a major morbidity. These morbidities include 
pulmonary hypertension, intraventricular hemorrhage (IVH) grade III/IV, stage II/III 
necrotizing enterocolitis (NEC), hypoxic-ischemic encephalopathy, seizures, and 
bronchopulmonary dysplasia.4 It is important to discover ways to decrease the 
development and improve the management of these and other morbidities as they have 
immediate and long-lasting effects on the neonate.  
1.1.2 Exposure of the Premature Neonate to Antenatal Magnesium Sulfate  
 
The use of magnesium sulfate in prenatal management has become increasingly 
prevalent over the past few decades. It is now standard of care for seizure treatment in 
maternal eclampsia, seizure prevention in maternal preeclampsia, and fetal 
neuroprotection in women at risk of delivering preterm at <32 weeks’ gestational age 
(GA).5,6 Additionally, some institutions use magnesium sulfate as a tocolytic agent for 
short-term prolongation of pregnancy to allow for antenatal corticosteroid administration, 
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although studies have proven there is no benefit to its use and there may be increased risk 
of fetal mortality.7 As such, it is common for the very preterm neonate to have had 
antenatal magnesium sulfate exposure.  
A 2009 systematic review of five randomized controlled trials (RCTs) revealed 
that antenatal magnesium sulfate therapy reduces the risk of cerebral palsy and gross 
motor dysfunction in the very preterm neonate without increasing pediatric mortality.6 
This finding was an important breakthrough for the medical community and was 
sufficient to bring magnesium sulfate into mainstream use for fetal neuroprotection. 
However, the studies in the systematic review included the use of antenatal magnesium 
for varying indications, and maternal magnesium sulfate regimens differed in dosing and 
timing.6 Thus, a number of questions regarding the use as well as the risks of antenatal 
magnesium sulfate remained unanswered. Observational studies have since suggested 
that antenatal magnesium sulfate therapy could be associated with neonatal 
gastrointestinal morbidities such as feeding intolerance (FI), NEC, and spontaneous 
intestinal perforation (SIP).8-10 Most of these studies, however, fail to account for 
different amounts of magnesium exposure. 
1.1.3 Magnesium Sulfate Therapy and Neonatal Magnesium Levels  
 
Much of the existing literature evaluates neonates who have been exposed to 
antenatal magnesium sulfate as one large cohort. As the ideal dose and timing of 
antenatal magnesium sulfate has not been standardized, and as the speed of labor and 
delivery differs, each mother-fetus dyad may receive a different amount of magnesium 
sulfate, resulting in a different final neonatal magnesium concentration.11 Additionally, a 
number of other dyad characteristics can impact neonatal magnesium concentration such 
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as maternal BMI, multiple gestation pregnancies, and maternal and neonatal renal 
function.12,13 The result is a spectrum of neonatal magnesium concentrations in the cohort 
of neonates exposed to antenatal magnesium sulfate. Thus, it is imperative that a future 
study clarifying the association of antenatal magnesium sulfate and adverse 
gastrointestinal outcomes accounts for neonatal magnesium concentration.  
1.1.4 Feeding Intolerance 
 
Feeding intolerance, or difficulty digesting enteral feeds, is common among very 
preterm neonates and is one of the adverse outcomes that could be associated with 
exposure to magnesium sulfate. A retrospective study by Belden et al. provides support 
for this association. In this study, neonates ≥24 weeks’ GA who had FI were found to 
have been exposed to a larger total dose of antenatal magnesium sulfate than neonates 
who did not have FI (70.4 +/- 52.3g vs 47.4 +/- 40.1g; p=0.04).8  
Neonatal FI can be a benign condition related to an immature gastrointestinal 
tract; however, it can also lead to suboptimal nutrition and prolonged use of intravenous 
nutrition which increases the risk of neonatal cholestasis and septicemia. Additionally, FI 
may lead to additional laboratory testing and diagnostic imaging, affect length of stay in 
the hospital, and subsequently increase healthcare cost.14,15 
FI is a clinical diagnosis based on signs and symptoms which include abdominal 
distension, emesis, gastric residuals, and episodes of apnea, bradycardia, and oxygen 
desaturation.14,16 As these signs and symptoms overlap with stage I NEC in Bell’s 
modified staging criteria, FI can suggest underlying NEC.14,17 Primary management of FI 
involves reducing enteral feeding volumes, delaying enteral feeding advancement, 
temporarily discontinuing enteral feeds, or switching the composition of feeds.14  
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If an association between elevated magnesium and neonatal FI exists as 
observational studies suggest, then elevated neonatal magnesium level could provide an 
explanation for benign FI and decrease unnecessary testing and healthcare cost in a 
neonate with signs of FI who is otherwise well-appearing. It could also create an 
opportunity for early recognition of FI to reduce adverse consequences outlined above.  
1.1.5 Necrotizing Enterocolitis and Spontaneous Intestinal Perforation  
 
In addition to FI, NEC and SIP are gastrointestinal morbidities that impact very 
preterm neonates and could be linked to antenatal magnesium exposure.9,10 NEC is the 
most common life-threatening surgical emergency in neonates.16,17 A 2018 systematic 
review reveals a 6.8% incidence of NEC among very preterm neonates in the United 
States.18 The most severe cases of NEC may result in death or the need for surgical bowel 
resection leading to short bowel syndrome, growth failure, cholestasis, or liver failure.17 
Other complications include intestinal stricture formation, respiratory and cardiac 
insufficiency, later-onset neurodevelopmental injury, and sepsis.17,19  
The exact pathophysiology of NEC is unknown and is likely multifactorial; 
however, it presents most often with the initiation or progression of enteral feeds.16 NEC 
may result from an abnormal balance of gut microbiota followed by intestinal injury, 
which activates an inflammatory immune response and leads to intestinal necrosis, 
allowing gas-forming organisms to invade the bowel.16,17,20 The most important risk 
factor for the development of NEC is prematurity, especially for neonates who are very 
low birth weight (VLBW) or small for gestational age (SGA).17Another risk factor may 
be anemia requiring packed red blood cell transfusion. This may be due to decreased 
oxygen delivery and increased oxygen requirement associated with feeding, followed by 
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a reperfusion-type intestinal injury as a result of transfusion.17,21 Finally, human milk has 
been shown to be an important protective factor against the development of NEC.17,22  
Although SIP is prevalent in a similar patient population and manifests with 
similar clinical signs, it has recently been recognized as a distinct clinical entity from 
NEC.23,24 Postnatal indomethacin and exogenous glucocorticoids have been found to be 
synergistic risk factors for SIP.24 The pathophysiology of SIP is thought to involve 
decreased intestinal perfusion or thinning of the intestinal lining leading to 
perforation.10,23 Although NEC and SIP can only be truly differentiated intraoperatively, 
physical examination and radiographic findings can support clinical diagnoses.10 Per a 
2014 prospective cohort of 177,618 VLBW neonates, SIP has an estimated mortality rate 
of 19% as compared to 38% for NEC.25  
As has been outlined, NEC and SIP most commonly affect very preterm neonates, 
and lead to severe outcomes including death or disability. Identifying neonates who are 
particularly at risk for developing these diseases is paramount. Wertheimer et al. notes 
that recognizing NEC [and SIP] early in its progression may improve outcomes, as it 
allows for early medical or surgical treatment.17,26 Therefore, it is critical to clarify if 
elevated neonatal magnesium concentration as a result of antenatal magnesium sulfate 
therapy is associated with increased risk for NEC or SIP. This could give clinicians the 
opportunity for increased monitoring and early intervention to reduce associated 
morbidity, mortality, and cost of NEC and SIP.  
1.2 Statement of the Problem 
Antenatal magnesium sulfate is effective in preventing and treating seizures in 
mothers with preeclampsia and eclampsia, respectively, and reducing the rate of cerebral 
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palsy in very preterm neonates. However, it is unclear whether elevated neonatal 
magnesium concentration as a result of antenatal magnesium sulfate therapy is associated 
with feeding intolerance and other adverse gastrointestinal outcomes including NEC and 
SIP.  Much of the literature surrounding this question is retrospective and compounded 
by problematic study design including inefficient power to draw conclusions, failure to 
account for neonatal magnesium concentration, and lack of representation of extremely 
preterm neonates. Nevertheless, these limited studies suggest that increased dose of 
antenatal magnesium sulfate, and presumably increased neonatal magnesium 
concentration, could be associated with neonatal feeding intolerance.  
1.3 Goals and Objectives 
To establish if magnesium concentration in umbilical cord blood at the time of 
delivery is associated with feeding intolerance and other adverse gastrointestinal 
outcomes, including necrotizing enterocolitis and spontaneous intestinal perforation, in 
very preterm neonates. 
1.4 Hypothesis 
The incidence rate of feeding intolerance as measured by time to full enteral feed 
in very preterm neonates is different among neonates in the middle and high terciles of 
magnesium concentration as compared to the low tercile of magnesium concentration in 
umbilical cord blood at the time of delivery after controlling for confounding.  
1.5 Definitions  
Time to full enteral feed – the time it takes to reach an enteral intake of 150 mL/kg/day 
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CHAPTER 2: REVIEW OF THE LITERATURE  
  
2.1 Introduction: Search Criteria  
During the period of August 2019 to June 2020, we conducted repeated searches 
of PubMed, Ovid Medline, Scopus, and Cochrane Library databases with the assistance 
of the librarians at the Yale School of Medicine. Primary searches were conducted using 
combinations of the MeSH terms “infant, premature,” “magnesium sulfate,” and key 
words “feeding intolerance” or “feeding tolerance.” Additional search terms included 
“nutrition, enteral,” “enterocolitis, necrotizing,” “intestinal perforation,” “first stool,” and 
“first feed.” We also examined the reference lists of all studies to further identify relevant 
papers. We included pertinent clinical studies, systematic reviews, and meta-analyses, 
with preference given to articles published in the past 10 years. All articles were written 
in the English language. 
This literature search demonstrates the uncertainty surrounding the association of 
antenatal magnesium sulfate and adverse gastrointestinal outcomes such as feeding 
intolerance in very preterm neonates. By analyzing pertinent studies and reviewing their 
limitations, we will demonstrate how our prospective observational study will help to fill 
the current gaps in research in a way that is novel, feasible, and realistic.   
2.2 Review of Empirical Studies   
2.2.1 The Use of Antenatal Magnesium Sulfate 
 
Magnesium sulfate is the medication of choice to prevent and treat seizures in 
mothers with preeclampsia and eclampsia, respectively.1,2 In a 2010 systematic review of 
fifteen RCTs, magnesium sulfate was found to reduce the risk of seizures by more than 
50% compared to placebo and to be superior to both phenytoin and nimodipine for this 
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purpose (relative risk (RR), 0.41; 95% confidence interval (CI), 0.29-0.58; number 
needed to treat (NNT), 100).1 Antenatal magnesium sulfate is also indicated for fetal 
neuroprotection in women at risk for preterm birth at less than 32-34 weeks’ gestation. 
This role was primarily established by five landmark studies published between 2002 and 
2008.3-7 A 2009 Cochrane Review of these five trials revealed that antenatal magnesium 
sulfate therapy significantly reduces the risk of cerebral palsy in the infant born at less 
than 32 weeks’ gestation (RR, 0.68; 95% CI, 0.54-0.87; five trials; 6145 infants). The 
NNT to prevent cerebral palsy in one baby is 63 (95% CI, 43-155) without an increase in 
mortality or morbidities.8 Following these studies, the World Health Organization has 
recommended the use of magnesium sulfate for fetal neuroprotection when delivery is 
expected at less than 32 weeks’ gestation and the American College of Obstetricians and 
Gynecologists (ACOG) has stated that physicians can elect to use magnesium sulfate for 
this indication.9,10  
Although antenatal magnesium sulfate therapy for neuroprotection of very 
preterm neonates is now standard practice, there remain uncertainties about associated 
morbidities and the ideal therapeutic regimen. Potential adverse neonatal outcomes 
associated with antenatal magnesium sulfate use described throughout the literature 
include but are not limited to, IVH11, hypotonia12, respiratory depression8,13, 
bronchopulmonary dysplasia14, patent ductus arteriosus (PDA)15, hypotension14, feeding 
intolerance16, necrotizing enterocolitis14, and spontaneous intestinal perforation.17 
Gastrointestinal outcomes such as FI, NEC, and SIP require further evaluation as existing 
studies are incomplete. 
2.2.2 Potential Mechanisms of Action of Magnesium on the Neonatal Bowel  
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Of the potential adverse neonatal outcomes associated with antenatal magnesium 
sulfate therapy, gastrointestinal problems are biologically plausible and have been the 
subject of numerous studies. There are two predominant physiologic theories on how 
magnesium impacts the bowel and could lead to FI, NEC, SIP, or other adverse 
gastrointestinal outcomes. First, magnesium antagonizes calcium in smooth muscle cells 
which reduces contractility leading to reduced GI motility. Hypomotility could lead to 
increased intraluminal pressure via increased water absorption, stool plug formation, and 
bacterial growth, which can eventually damage the immature intestine and lead to 
rupture.16,18 Second, magnesium causes vasodilation which could alter intestinal blood 
flow and impact tolerance to enteral feeds.19,20 A compounding factor is that magnesium 
sulfate is renally eliminated. Therefore, the immature renal function of preterm neonates 
can potentiate and prolong the effects of magnesium.16  
Observational studies have investigated whether antenatal magnesium sulfate 
exposure effects neonatal intestinal blood flow, as physiologic mechanisms suggest it 
could. A 2011 retrospective cohort study measured peak mean end-diastolic velocities in 
the superior mesenteric artery (SMA) of 56 neonates born <37 weeks’ GA who weighed 
<2500g at birth.19 The mean SMA blood flow velocity was similar in neonates with and 
without magnesium sulfate exposure; however, there was a negative correlation between 
SMA blood flow velocity and the number of hours between birth and time of 
measurement in the magnesium-exposed group that was not appreciated in the unexposed 
group (r=0.38; p=0.852). These findings suggest that magnesium could be exerting an 
effect on intestinal blood flow velocity in the immediate hours after birth.19 
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A 2015 prospective study measured daily Doppler flow measurements of the 
SMA in the first five postnatal days in 50 birth weight and GA-matched neonates who 
were exposed and non-exposed to antenatal magnesium sulfate and were born at 26-34 
weeks’ GA.21 Although blood flow velocities did not differ between the two groups, there 
was a trend toward increasing blood flow over time in the non-exposed group that did not 
occur in the exposed group (non-exposed, p<0.001; exposed, p=0.29). This finding could 
be due to the vasodilatory effects of magnesium. As magnesium levels decreased over the 
five days causing vasodilation to decrease, blood flow velocity did not increase in the 
exposed group to the degree that it did in the non-exposed group.21 Overall, these two 
studies suggest that magnesium could contribute to adverse gastrointestinal outcomes by 
attenuating the increase in intestinal blood flow velocity seen in neonates who have not 
been exposed to antenatal magnesium sulfate. 
As noted above, the immature renal function of preterm neonates can potentiate 
and prolong the physiologic effects of elevated magnesium concentration.16 Renal 
magnesium clearance in a neonate, especially a preterm neonate, is decreased during the 
first few days of life, resulting in elevated magnesium levels that persist for longer 
periods of time after delivery than in the mother.22 For example, the half-life of 
magnesium sulfate in women with normal renal function is four hours while the half-life 
of magnesium in neonates exposed to antenatal magnesium sulfate is greater than forty 
hours.23,24 Maternal magnesium toxicity appears to be concentration-dependent: a loss of 
reflexes occurs when serum magnesium concentration is above 8.5 mg/dL and respiratory 
paralysis occurs when serum magnesium concentration is greater than 12 mg/dL.23 
Similarly, adverse neonatal gastrointestinal effects such as reduced GI motility and 
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altered intestinal blood flow may be dependent on neonatal serum magnesium levels. In 
fact, Pryde and Mittendorf have hypothesized that magnesium has a therapeutic window 
in the neonate where a concentration too low fails to provide neuroprotection and a 
concentration too high is associated with poor outcomes in a dose-related fashion.7,25,26 
2.2.3 Antenatal Magnesium Sulfate and Adverse Effect: Feeding Intolerance  
 
Despite the plausible physiologic mechanism by which elevated neonatal 
magnesium levels can adversely affect bowel function, observational studies 
investigating a possible association between antenatal magnesium sulfate therapy and 
neonatal feeding intolerance have shown conflicting results.  
Data from a 2017 single-center retrospective observational study suggest an 
association exists between elevated neonatal magnesium level and enteral feeding 
intolerance. In this study, cumulative dose of maternal magnesium sulfate was compared 
to incidence of enteral FI in 83 neonates ≥24 weeks’ gestational age.16 Neonates found to 
have FI were exposed to larger cumulative magnesium sulfate doses than those who did 
not have FI (70.4 +/- 52.3 vs 47.4 +/- 40.1g; p=0.04), with those exposed to greater than 
80g being more likely to develop FI (44% vs 22%; p=0.04). Due to differences in 
maternal and neonatal baseline characteristics between neonates with and without FI, a 
multivariate logistic regression was performed which found that the strongest predictors 
of FI were cumulative maternal magnesium sulfate dose and gestational age.16 The data 
from this study are retrospective and need to be confirmed by a prospective study. 
Additionally, cumulative magnesium sulfate dose was used as a marker of neonatal 
magnesium sulfate exposure, but neonatal serum magnesium concentration was not 
measured.16 Although an increased total dose of maternal magnesium sulfate therapy may 
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be associated with an increased neonatal magnesium concentration, neonatal serum 
magnesium concentration should be measured to determine its association with FI.27,28 
Other retrospective and prospective observational studies have evaluated FI or 
time to full enteral feed (our measure of FI) as a secondary outcome and were 
underpowered to see an association even when, in some cases, raw data suggest one. A 
2015 prospective study discussed above compared SMA blood flow in neonates who 
were exposed to antenatal magnesium sulfate to weight and age-matched neonates who 
were not exposed. Secondary outcomes included time to reach full feeds, first meconium 
passage, and presence of FI defined as gastric residuals >50% on consecutive feedings, 
abdominal distension, or vomiting that resulted in failure to make the daily increments in 
feeding.21 No secondary outcomes reached statistical significance although 6 neonates 
(24%) in the magnesium-exposed group were feeding intolerant while only 2 neonates 
(8%) in the unexposed group were feeding intolerant (p=0.12).21 The study was limited 
by its small sample size. Additionally, the average GA of neonates in the study was 31 
weeks, so the study did not address a possible effect of magnesium exposure on FI in 
neonates born at lower GAs.  
A 2011 study evaluated clinical outcomes in neonates born at 24-32 weeks’ 
gestation who were either exposed to antenatal magnesium sulfate for neuroprotection 
(n= 289) or not exposed (n=186).22 Time to reach full enteral feeds, a secondary outcome, 
was delayed in neonates exposed to magnesium sulfate compared to those unexposed 
(36.6 +/- 30.7 vs 29.9 +/- 29 days; p=0.03). After correcting for GA and birth weight, this 
delay was no longer significant. The exposed group was further divided into four groups 
by serum magnesium levels obtained in the first 24 hours of life: <3 mg/dL, 3-<4.3 
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mg/dL, 4.3-<5.5 mg/dL, and ≥5.5 mg/dL. Time to reach full enteral feed was not 
associated with increasing magnesium concentration in these groups (35 +/- 25, 37 +/- 
28, 39 +/- 39, 35 +/- 26 days; p=0.85) although the large standard deviations suggest 
great variability in outcomes, decreasing our confidence in these results.22 
The same group performed a 2017 retrospective observational study that 
correlated serum magnesium levels obtained within the first 48 hours of life of 304 
neonates born 24-34 weeks’ GA with immediate neonatal outcomes.29 Similar to the 
2011 study, the 225 neonates who were exposed to magnesium sulfate took longer to 
achieve full feeds than the 63 neonates who were not exposed (16 days (10-27.5) vs 10 
days (6-17); p <0.01), where values are expressed as medians (Q1:25% to Q3:75%). Data 
for time to full feed were missing for 16 neonates. As in their prior study, exposed 
neonates were further stratified based on magnesium concentrations: Group 1 <2.5 mg/dL 
(n=55), Group 2 ≥2.5-4.5 mg/dL (n=154), Group 3 ≥4.5 mg/dL (n=17). Increasing 
neonatal magnesium concentrations were associated with longer time taken to achieve 
full feeds (13 (9-13.5), 18 (11-27), and 32 (17.5-45.5) days, respectively; p <0.01) where 
values are expressed as medians. A regression analysis was performed to control for birth 
weight and multiple gestation using Group 2 as a reference, which rendered this result not 
statistically significant. The probability of a type II error (ß) was 0.02 with a 95% CI (-
0.06-0.09) for Group 1 and -0.02 (-0.14-0.09) for Group 3.29 
As mentioned, these two studies were underpowered to see an association 
between magnesium concentration and time to full feed. Although their retrospective 
design was successful in generating the hypothesis that an association could exist, a 
larger prospective cohort study is needed. Additionally, magnesium concentrations were 
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obtained from serum up to 24 or 48 hours after birth, which introduced information bias 
as data were not extracted at the same point in time and likely do not represent each 
patient’s maximum magnesium concentration after birth.22,29 Finally, the number of 
neonates in Groups 1 through 3 of the 2017 study were dissimilar. Only 17 neonates were 
in Group 3 as compared to 154 neonates in Group 2, the reference group, which could 
have resulted in an inaccurate representation of adverse outcomes in this group and 
decreased the likelihood of finding an association.29 
Finally, a 2011 retrospective study mentioned above evaluating intestinal blood 
flow in neonates <37 weeks’ GA exposed and unexposed to antenatal magnesium sulfate 
additionally measured time to full enteral feed as a secondary outcome.19 They found no 
difference in days to achieve full enteral feeding volumes between neonates exposed to 
antenatal magnesium sulfate compared to neonates unexposed (14.5 +/- 11.4 vs 16.5 +/- 
13.6 days; p=0.58), arguing against an association between antenatal magnesium sulfate 
and neonatal FI.19  
Although only one observational study described above found that increased 
antenatal magnesium sulfate dose was significantly associated with FI in very preterm 
neonates, the raw data of additional studies suggest than an association could exist 
between elevated neonatal magnesium and FI. By performing a larger prospective study 
with a primary outcome of feeding intolerance and measuring neonatal magnesium levels 
at the time of delivery, our study will be able to clarify this association.  
2.2.4 Antenatal Magnesium Sulfate and Adverse Effects: NEC and SIP 
 
Multiple RCTs have looked at the incidence of necrotizing enterocolitis in 
preterm neonates that have been exposed to antenatal magnesium sulfate. Data from three 
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of the landmark neuroprotection RCTs discussed above showed no statistical difference 
in the incidence of NEC among those exposed to magnesium sulfate and those exposed to 
placebo.3,4,30 A subgroup analysis of these three studies in a 2009 meta-analysis of 
antenatal magnesium sulfate for the prevention of cerebral palsy in infants less than 34 
weeks’ gestation revealed that neonates exposed to antenatal magnesium sulfate had a 
higher incidence of NEC (155 of 2169, or 7.1%) than those unexposed (131 of 2218, or 
5.9%), although the result did not quite achieve statistical significance (RR, 1.23; 95% 
CI, 0.98-1.54).14 The three RCTs included in this evaluation all had a Modified Jadad 
score of 8 which indicates the highest quality of methods including successful 
randomization, appropriate double blinding and concealment, and >95% follow-up of 
fetuses.14  
There have been multiple secondary analyses of one of these studies, the 2008 
Maternal Fetal Medicine Units Beneficial Effects of Antenatal Magnesium (MFMU 
BEAM) trial, a multicenter RCT.4 A 2016 secondary analysis of the de-identified data set 
demonstrated a significant association between antenatal magnesium sulfate and the 
composite of severe NEC or death in neonates born less than 26 weeks’ gestation after 
controlling for confounders such as GA and SGA (AOR, 1.90; 95% CI, 1.12-3.22; 
p=0.017).31 The association was not noted in a larger group of 697 neonates with 
gestational ages up to 27.9 weeks. A secondary analysis published in 2019 included 648 
neonates born between 24 to less than 32 weeks’ gestation who had cord blood 
magnesium levels drawn at birth.32 The aim of this study was to determine the effects of 
antenatal magnesium sulfate on non-neurologic neonatal outcomes including severe NEC 
with respect to cord blood magnesium level. Neonates were divided into quintiles of 
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magnesium cord blood levels and outcomes were compared between the highest quintile 
(≥2.9 mg/dL) and the lowest quintile (≤ 1.5 mg/dL). There was a significant increase in 
the rate of NEC in the highest vs the lowest quintile, (6.6% vs 2.8%; OR, 2.41; 95% CI, 
1.11-5.24; p=0.02) but this was no longer significant after multivariate logistic regression 
adjusted for GA, birth weight, and treatment group (AOR, 1.56; 95% CI, 0.51-5.58).32  
As secondary analyses of a quality RCT, both studies have strong internal 
validities with low information bias. However, there are several limitations of such 
analyses. First, secondary analyses are limited by variables collected by the parent study. 
For example, the specifics of care in the neonatal intensive care unit (NICU) are 
unknown.31 Second, there could be overlap of SIP in the diagnosis of NEC as this was not 
a contemporary cohort and only recently have NEC and SIP been well-distinguished.31 
Additionally, 31% of neonates were missing cord blood magnesium levels in the 2019 
study which could have impacted findings. Furthermore, the majority of neonates in this 
study were 30-32 weeks’ GA so an association between magnesium and NEC may have 
been missed in neonates of lower gestational ages.32  
There have been fewer investigations into the relationship between antenatal 
magnesium sulfate and neonatal spontaneous intestinal perforation. A 2014 single-center 
prospective cohort study evaluated the association between antenatal magnesium sulfate 
for neuroprotection and SIP among 155 extremely low birth weight (ELBW) neonates.17 
Both gestational age (OR, 6.0; 95% CI, 2.4-18.2) and total magnesium sulfate dose (OR, 
9.3; 95% CI, 1.04-104.6) were associated with SIP and mortality with a marked increase 
in SIP once maternal magnesium exposure reached 100g. Overall, there was increased 
SIP and mortality in neonates born less than 25 weeks’ gestation. After multivariate 
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analysis, the administration of postnatal hydrocortisone was also independently 
associated with the risk of SIP or death (p=0.021).17 The authors discuss a synergistic 
effect of hypomotility from magnesium and submucosal thinning from hydrocortisone 
resulting in SIP. Although this study is limited in its small sample size and its inability to 
control for possible covariates in local management, it suggests the need for further 
investigation into the relationship between magnesium exposure and SIP, especially 
among neonates born <25 weeks’ GA.17 
 Conversely, two large retrospective cohort studies have found no statistically 
significant association between antenatal magnesium sulfate exposure and SIP. First, a 
2017 multicenter retrospective cohort study evaluated the relationship between antenatal 
magnesium sulfate and SIP in 28,035 ELBW infants.33 Out of 11,789 infants exposed to 
antenatal magnesium sulfate, 2.9% developed SIP, and out of 16,246 unexposed infants, 
2.3% developed SIP (AOR, 1.08; 95% CI, 0.91-1.29). This study has strong external 
validity as it took place at many diverse study centers and its large number of participants 
allowed control for multiple confounders. Limitations include the retrospective design 
and lack of information recorded about antenatal magnesium therapy including dose, 
timing, and indication for its use. Neonatal magnesium levels were not routinely 
measured, so no association between magnesium level and risk of SIP could be assessed. 
Additionally, if an infant was transferred outside of the study network, outcome data 
were not recorded.33  
Second, a 2017 population-based retrospective cohort study evaluated the 
association between antenatal magnesium sulfate and either NEC or SIP among 4,355 
neonates born less than 28 weeks’ gestation.34 Similar to the previous study, this study 
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found no difference in the odds of NEC (AOR, 0.92; 95% CI, 0.75-1.14; p=0.45) or SIP 
(AOR, 1.05; 95% CI, 0.75-1.48; p=0.75) between neonates exposed and unexposed to 
antenatal magnesium sulfate after adjusting for multiple confounders. This study is 
strengthened by its large sample size and ability to control for risk factors for SIP.34 It 
suffers from the same limitations as the previous study, including retrospective design 
and the fact that neonatal magnesium concentrations were not routinely measured. 
Antenatal magnesium sulfate exposure has even been shown to have possible 
beneficial effects on the neonatal gastrointestinal tract. One 2019 retrospective 
observational study evaluated 302 inborn neonates ≤28 weeks or ≤1000g and found that 
antenatal magnesium sulfate exerted a protective effect in which every 10g increase in 
cumulative maternal dose correlated with an 18.9% decrease in SIP, NEC or death prior 
to discharge, especially among neonates who were SGA.35 Although this study is limited 
by its retrospective single center design, it is unique in its finding and further highlights 
the need to clarify the relationship between magnesium, NEC and SIP. 
In a 2019 review, Bhawan Deep Garg evaluated the risks and benefits of antenatal 
magnesium sulfate in very preterm neonates using published systematic reviews, meta-
analyses, RCTs, and observational studies.18 He concluded that there is not enough 
evidence to prove that magnesium sulfate is associated with gastrointestinal 
complications. Thus, it should continue to be used according to protocol with high 
suspicion for GI complications in extremely preterm neonates.18 Our review reveals that 
evidence needed to clarify the relationship between antenatal magnesium exposure and 
NEC or SIP would need to overcome the limitations of the above studies. Thus, a future 
study would require prospective investigation of a contemporary cohort of neonates, 
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especially those of lower GA, with consideration of neonatal magnesium concentration 
and minimal missing data.  
2.2.5 Antenatal Magnesium Sulfate and Parameters of Gastrointestinal Function 
 
Three other parameters that may reflect an influence of magnesium exposure on 
gastrointestinal function in preterm neonates are time to first enteral feed, time to first 
stool, and number of abdominal X-rays in the first 30 days of life. Thus, they will be 
evaluated as exploratory secondary outcomes in our proposed study.  
The timing of first enteral feed in very preterm and VLBW neonates may be 
related to feeding tolerance. Early research suggested that early enteral feeds could 
increase the risk of NEC.36 However, early enteral feeding aids the development of the 
gastrointestinal tract, and holding feeds for greater than 72 hours can lead to intestinal 
atrophy and loss of function. Holding feeds could then contribute to FI when enteral 
feeds are introduced.37 A 2014 systematic review of nine RCTs (n=1106 infants) found 
that delayed introduction of enteral feeds led to delay in time to reach full enteral feed 
(reported median differences 2-4 days), but there was no difference in risk of NEC or all-
cause mortality between early and late enteral feeding groups.36 We believe it is 
important for our study to note any difference in time to first feed between our groups of 
patients with different magnesium concentrations and how it could contribute to delay in 
full enteral feed and FI.  
 Time to first stool is often used as a representation of gastrointestinal motility.38 
There are mixed data regarding the association between elevated magnesium and delayed 
time to first stool. In a 2017 retrospective study discussed above, time to first stool was 
evaluated as a secondary outcome and compared between a group of neonates with FI 
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and higher total dose of antenatal magnesium sulfate and a group of neonates without FI 
who were found to have received a lower total dose of antenatal magnesium sulfate.16 
Time to first stool was found to be significantly longer in the feeding intolerance group 
(3.4 vs 1.8 days; p <0.05). Delayed first stool suggests that decreased gastrointestinal 
motility could be a contributing factor to feeding intolerance secondary to magnesium 
sulfate exposure.16 A 1982 prospective cohort study (n=56) found a similar result. Fifty 
percent of neonates born <36 weeks’ gestation to hypertensive mothers treated with 
magnesium sulfate had delayed stooling >24 hours compared to only 21% of age-
matched, unexposed controls.38 Alternatively, a number of prospective and retrospective 
observational studies have found no difference in time to first stool between neonates 
exposed to antenatal magnesium sulfate and those unexposed.12,21,39 To the best of our 
knowledge, there are no studies that compare neonatal magnesium concentration at the 
time of delivery to time to first stool.  
 The number of abdominal x-rays performed during the first month of life can be 
used as a surrogate assessment for clinician concern about feeding intolerance or other 
gastrointestinal pathology. Abdominal x-rays are often obtained in the setting of neonatal 
feeding intolerance and are used to diagnose and monitor the progression of 
gastrointestinal disease.40 Additionally, this outcome is worth exploration as it is a source 
of neonatal radiation exposure and significant healthcare cost. 
2.2.6 Determinants of Neonatal Magnesium Concentration 
 
The landmark studies that brought maternal magnesium sulfate into clinical use 
for fetal neuroprotection used different loading doses, maintenance infusion rates, and 
durations of maternal magnesium sulfate therapy.8 As no dosing regimen was proven to 
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be superior, ACOG recommended that clinicians base their treatment guidelines on one 
of the larger trials.9 Importantly, the relationship between maternal magnesium sulfate 
therapy (dose, duration, and timing of treatment), maternal serum magnesium 
concentration, and neonatal serum magnesium concentration is unclear. All three factors, 
as well as the delayed renal clearance of magnesium and persistence of elevated 
concentrations described earlier, may impact neonatal well-being.  
Magnesium ions cross the placenta readily by either passive or active facilitated 
transport.15 In neonates born at 24-34 weeks’ GA, Narasimhulu et al. found that maternal 
magnesium concentration predicts neonatal magnesium concentration obtained in the first 
48 hours of life (r=0.72, p<0.001). They also found that total maternal magnesium sulfate 
dose (r=0.66; p<0.0001) and duration of therapy (r=0.70, p<0.0001) predict neonatal 
magnesium concentration.29  They suggest that total maternal dose or duration of therapy 
should be thought of as a surrogate for fetal exposure rather than maternal magnesium 
concentration, which may be more representative of maternal renal clearance of 
magnesium sulfate.29 Other studies have confirmed that total maternal magnesium sulfate 
dose and duration of therapy predict neonatal magnesium concentration.27,28 By using 4.5 
mg/dL as the magnesium concentration beyond which neonates may experience increased 
morbidity and mortality,22 García Alonso et al. predicted that maternal doses ≤20 g of 
antenatal magnesium sulfate given continuously over 16 hours are safe.28 In summary, 
these studies all suggest that total maternal magnesium dose is the best predictor of serum 
magnesium concentration in neonates.28  
Other factors may contribute to the final serum magnesium concentration in 
preterm neonates. These include maternal BMI29, maternal albumin level29, multiple 
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gestation pregnancies29, neonatal GA28,41, neonatal birth weight28,29,41, neonatal renal 
function42, and neonatal nutrition42. The timing of maternal magnesium therapy may be a 
final important consideration. A 2016 secondary analysis of the 2008 MFMU BEAM 
Trial found that therapy less than 12 hours prior to delivery was associated with reduced 
odds of neonatal cerebral palsy at 2 years compared to therapy greater than or equal to 12 
hours prior to delivery (AOR, 0.41; 95% CI, 0.18-0.91; p=0.03).4,43 The multitude of 
factors which can impact the concentration of magnesium in a neonate make it clear that 
a study attempting to assess the effect of magnesium on neonatal FI, NEC, or SIP must 
take into account neonatal magnesium concentration.  
2.3 Confounding Variables   
The relationship between neonatal magnesium concentration and gastrointestinal 
outcomes is difficult to isolate as there are a multitude of potential confounding variables 
identified in the literature that could influence this relationship. Variables include 
maternal factors such as age, BMI, and race, perinatal factors such as reason for 
magnesium sulfate therapy, hospital of delivery, antenatal steroids, prolonged rupture of 
membranes, mode of delivery, and multiple gestations, and neonatal factors such as GA, 
birth weight, sex, SGA, 5-minute Apgar score, feeding with human milk, sepsis, postnatal 
steroids, postnatal indomethacin for IVH prophylaxis, and postnatal NSAID treatment for 
PDA. Although many of these variables have only been shown in studies to relate to the 
risk of NEC, they may also relate to the risk of feeding intolerance.  
2.3.1 Maternal Variables  
 
Studies suggest that maternal variables can impact magnesium concentration. In a 
retrospective study discussed above, higher maternal BMI was found to be associated 
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with lower neonatal magnesium concentration (ß = -0.29, p<0.001). Maternal age and 
race were not correlated with neonatal magnesium concentration.29 
 In studies conducted in the United States, black race has been associated with 
increased risk for developing NEC whereas maternal age, BMI, and maternal education 
have not been associated with NEC.44,45 Thus, it is important to consider maternal age, 
BMI, and race as these factors could potentially confound results.  
2.3.2 Perinatal Variables  
 
A retrospective study discussed above found that multiple gestation pregnancies 
were associated with lower magnesium concentrations (ß = -0.14; p=0.02) and maternal 
preeclampsia was associated with higher neonatal magnesium concentration (ß = 0.19, 
p=0.003).29 Factors that have been associated with increased risk for NEC include 
preeclampsia in mothers of neonates born <29 weeks’ GA and premature rupture of 
membranes.44,46,47 A Cochrane Systematic Review found that the use of antenatal steroids 
reduces the relative risk of NEC by 50% (RR, 0.50; 95% CI, 0.32-0.78; ten trials; 4702 
infants).48 Additionally, there are conflicting data regarding Cesarean delivery and risk 
for NEC, thus this factor must be considered.44 Finally, one study found that antenatal 
steroid use shortens the time to first stool.39 We will also consider hospital of delivery as 
slight differences in care may lead to a difference in outcomes.  
2.3.3 Neonatal Variables  
 
The most common covariates identified in the literature are gestational age and 
birth weight of the neonate. There are increased rates of FI, NEC, and SIP with both 
lower GA and with lower birth weight.49,50 Additionally, lower GA and lower birth 
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weight are associated with higher magnesium concentration.41 Therefore, it is important 
to include both of these neonatal characteristics as covariates. 
In addition to GA and birth weight, several other potential neonatal covariates 
have been identified that may increase or decrease the risk of our primary or secondary 
outcomes. Neonates who are SGA, have a low Apgar score, or who develop sepsis are at 
increased risk for developing NEC.44,47,51A 2017 systematic review reveals that feeding 
with human milk can decrease both FI and NEC.52 Postnatal indomethacin and postnatal 
steroids are co-risk factors for the development of SIP.53  
Two NSAIDs, indomethacin and ibuprofen, are used to treat PDAs in preterm 
infants and are known to have gastrointestinal side effects. Indomethacin decreases 
intestinal blood flow, and both Indomethacin and Ibuprofen decrease intestinal mucosal 
barrier function.37 These effects could lead to bacterial colonization when enteral feeding 
is introduced, so enteral feeding is frequently delayed while neonates are receiving these 
medications. Delay in feeding advance regimens, however, could increase the risk of FI 
when enteral feeds are re-introduced.37 Therefore, postnatal NSAID use must be closely 
monitored as a potential covariate. 
2.4 Relevant Methodology   
 This portion of the literature review includes a review of relevant methodology to 
the proposed study. A more detailed explanation of the proposed study methods can be 
found in Chapter 3.  
2.4.1 Study Design and Setting  
 
The proposed study will be a multicenter prospective observational study 
examining whether there is a difference in FI among very preterm neonates divided into 
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terciles based on magnesium concentration in their umbilical cord blood at the time of 
delivery. Although a randomized controlled trial is the gold standard study design, we 
selected a prospective cohort design as we could not meet the equipoise principle 
required of an RCT.54 Since the use of antenatal magnesium sulfate is now standard of 
care for fetal neuroprotection in neonates <32 weeks’ gestation, it would be unethical to 
assign mothers to not receive antenatal magnesium sulfate. In addition, our primary 
exposure is neonatal magnesium concentration at the time of delivery, which cannot be 
randomized.  
The study centers include the three Level IV NICUs in Connecticut and Rhode 
Island. These centers were selected because they have the highest capability of caring for 
critically ill newborns; thus, they deliver the highest volume of the desired population, 
very preterm neonates, to fulfill our study’s sample size.55 Additionally, it is unlikely that 
neonates will be transferred to another hospital for specialty care, increasing the 
likelihood that we will have a complete data set.  
 Given the degree of prematurity of our study population, all neonates are admitted 
to the NICU at the time of delivery. We plan to follow neonates from the time of birth 
until the time of discharge from the hospital or up until four months of their hospital stay. 
Based on prior studies, our outcomes of FI, NEC, and SIP occur by around one month of 
life.29,31,33,40 We will follow each infant for an additional three months to ensure that we 
capture all measures of our primary and secondary outcomes.  
2.4.2 Sampling for Study Population   
 
 In terms of sample selection, convenience sampling carries its own risk of 
selection bias; however, given the relatively rare nature of birth at <32 weeks’ GA, we 
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will need to use convenience sampling in order to recruit our necessary sample size. This 
is consistent with previous studies with similar populations.15,17,28 
2.4.3 Selection Criteria 
 
 The inclusion and exclusion criteria for the proposed study have been designed to 
be consistent with the literature and to allow the results of this study to be generalizable 
to very preterm neonates who are exposed to antenatal magnesium sulfate. Inclusion 
criteria include being born at <32 weeks’ gestation at one of our study centers with 
antenatal exposure to magnesium sulfate for any purpose. Exclusion criteria include 
neonates born at ≥32 weeks’ gestation, outborn neonates, and neonates who have not 
been exposed to antenatal magnesium sulfate. Additional exclusion criteria include 
neonates with major congenital malformations or neonates with chromosomal 
abnormalities as defined in prior studies.16,17,27,29,31-34 These two criteria would introduce 
significant confounding that we would be unable to control for. 
2.4.4 Exposure  
 
 Our primary exposure will be magnesium concentration in umbilical cord blood at 
the time of delivery. As this measurement is made at birth, it is the most accurate 
representation of magnesium sulfate exposure and defines the highest neonatal 
magnesium concentration.13  
 We plan to divide our primary exposure into three groups by terciles of 
magnesium concentration since data regarding average magnesium concentration in 
neonates exposed to magnesium sulfate are varied. Rigo et al. performed a meta-analysis 
in 2017 of 47 eligible studies comprised of 992 preterm and term neonates and found that 
the average neonatal serum magnesium level at birth was 3.13 mg/dL (95% CI, 1.22-
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5.05).42 This evaluation included preterm and term neonates, and there was high 
variability in the included studies (I2 = 99.1%; p < 0.001).42 While defining groups by 
upper and lower limits of magnesium concentration would most efficiently group similar 
concentrations, it could result in groups with uneven numbers of subjects that are 
underpowered to detect a difference in outcomes. Additionally, we do not feel confident 
assigning concentration cut-offs to define groups due to the variability of average 
magnesium concentration seen above. By dividing groups by terciles of magnesium 
concentration, we increase the likelihood of having an equivalent number of neonates in 
each group for final analyses. 
2.4.5 Primary Outcome  
 
 The primary outcome for the proposed study will be FI measured as time to full 
enteral feed (150 ml/kg/day). Throughout the literature, there are a number of ways to 
define FI, none of which have been validated as superior. For example, one study defined 
FI as “presence of gastric residuals greater than 50% on consecutive feedings, abdominal 
distention, or vomiting that resulted in failure to make daily increments in feeding,”21 
while another study defined FI as a composite outcome of deviations from the research 
institution’s standard NICU feeding protocol consisting of deviation in time to initiation 
of enteral feeds, time to non-trophic enteral feeds, or time to full enteral feeds.16 As the 
incidence of feeding intolerance will likely be high in our very preterm population, using 
a definition that is operationalized as time to an event will allow us to compare the 
severity of FI between groups instead of simply looking at its presence or absence. We 
believe that the signs of FI included in other definitions of FI such as gastric residuals 
>50% on consecutive feedings, abdominal distention, and significant emesis will be 
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captured by our measurement, as they should lead to a delay in the time to full enteral 
feed. For example, Yale New Haven Children’s Hospital’s (YNHCH) NICU feeding 
protocol, which will be adopted by all three study centers, states that if signs of FI are 
present, an abdominal exam should be performed and feedings should be held for at least 
six hours, pending further evaluation.  
2.4.6 Secondary Outcomes 
 
 NEC and SIP will be defined as in reviewed studies to keep outcomes consistent 
and generalizable. 29,31,34,35,56  
2.4.7 Confounders  
 
As noted above, there are a number of variables that could affect both magnesium 
concentration as well as the incidence of our primary and secondary outcomes. We plan 
to integrate as many covariates as possible to limit their effect. As modeled in reviewed 
studies, we will operate under the assumption that if factors that influence the frequency 
of our outcomes are not statistically significantly different between the three study 
groups, then their effect will cancel one another out. Possible confounders that are 
statistically different between groups on univariate analysis will be adjusted for in 
regression models to determine if they are significant covariates.28,29,34,35,41 It is likely that 
many characteristics will be similar within each group. For example, all mothers at risk 
for very preterm delivery should receive antenatal steroids; therefore, the percent of 
neonates exposed to antenatal steroids should be similar among the three groups.  
We plan on controlling for gestational age by stratifying our data analysis into 
neonates <25 weeks’, 25-27 and 6/7 weeks’, and 28-31 6/7 weeks’ GA as performed in 
prior studies.15,34 Additionally, multiple studies have noted that more data are needed for 
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extremely preterm neonates.18,32 By stratifying our analysis, we will be able to evaluate 
the association between magnesium concentration in neonates with lower GA and 
gastrointestinal outcomes more clearly. 
Of note, we expect increased total dose and duration of maternal magnesium to be 
correlated with umbilical cord magnesium concentration, as multiple studies have noted 
above.27-29 These influence the independent variable directly rather than confound 
outcomes. Thus, they do not need to be analyzed in a subgroup analysis.  
2.4.8 Sample Size and Statistical Significance   
 
 Though many studies discussed above evaluated feeding intolerance or time to 
full enteral feed as a secondary outcome, few studied it as a primary outcome. Therefore, 
most studies were not powered to see an effect on FI and could not be used to determine 
an expected effect size. One study that measured time to full enteral feed in days found 
the median survival to be 13, 18, and 32 days for neonates with low (<2.5 mg/dL), 
medium (≥2.5-4.5 mg/dL), and high (≥4.5 mg/dL) serum magnesium concentrations, 
respectively.29 Two differences between this study and our proposed study are important. 
First, our study utilizes umbilical cord blood at the time of delivery rather than serum 
blood after delivery. Due to the long half-life of magnesium in neonates, we assume that 
our magnesium levels will be similar or slightly higher than the levels obtained in this 
study.24 Second, our study divides neonates into terciles in order to have an even number 
of neonates in each group, regardless of the average magnesium concentration. If there is 
a relatively small range of magnesium concentrations in our study, the between group 
differences will not be as large as in this study where groups were created by defined 
concentration cut-offs.29 Even so, by only using median survival data from low and 
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medium groups in our calculation, we have increased the confidence that we will at least 
be able to detect a difference between our low and high tercile groups.  
Although our systematic literature review has led us to evaluate the adverse 
effects of elevated neonatal magnesium, we cannot rule out that magnesium sulfate could 
exert a protective effect on the intestine of SGA infants, as one study has suggested 
above.35 Thus, we have utilized a two-tailed calculation so that we will be able to detect a 
difference, if it exists, in either direction. The reviewed literature is typically powered 
based on the specific primary outcome measure to an alpha of 0.05 and beta of 0.20, 
which we will follow. Our sample size is limited by the number of inborn neonates <32 
weeks’ GA at our three study centers so we needed to work backwards from the fixed 
sample size and median survival discussed above to identify the hazard rate we would be 
powered to detect. Our final crude sample size is 486 (162 neonates per tercile) which 
includes 120 neonates to control for four covariates (10 per group per covariate). Our 
adjusted analysis will be able to detect a hazard rate as small as 0.68. Our sample size 
calculation can be found in its entirety in Appendix D. 
2.5 Conclusion 
Multiple studies have looked at the potential associations of antenatal magnesium 
exposure and neonatal outcomes, particularly FI, NEC, and SIP. However, these studies 
have several shortcomings. Most studies compare antenatal magnesium sulfate exposure 
to lack of exposure and do not measure neonatal magnesium concentration. We have 
shown that there are many factors that may affect neonatal magnesium levels, so studies 
that only record maternal treatment but do not assess neonatal magnesium level may not 
accurately assess the effect of magnesium on neonatal FI and risk of NEC or SIP. While a 
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few studies have measured neonatal magnesium levels, only one study utilized 
measurements from umbilical cord blood, which most accurately measures the neonate’s 
greatest magnesium level.32 Finally, many of the studies enrolled only small numbers of 
patients, under-enrolled extremely preterm neonates, were retrospective, or did not 
adequately control for confounding factors. In summary, our proposed study will fill in 
significant gaps regarding the important question of whether maternal magnesium 
therapy and subsequent elevation in neonatal magnesium concentration is associated with 
FI, NEC, or SIP. It will do so by recruiting a large sample at multiple study centers with 
appropriate demographic representation, measuring neonatal umbilical cord magnesium 
concentration at the time of delivery, following neonates prospectively, and conducting a 
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CHAPTER 3: STUDY METHODS 
 
3.1 Study Design 
 The proposed study will be a multicenter prospective cohort trial to analyze the 
association between magnesium concentration in umbilical cord blood of very preterm 
neonates and feeding intolerance from birth until discharge from the NICU or until four 
months of life. A consent form to participate in the study for self and child will be 
reviewed and signed. Next, an intake survey as well as chart review will extract maternal 
demographic data and features of maternal magnesium sulfate administration. Neonates 
born at less than 32 weeks’ gestation will have an umbilical cord blood sample taken at 
the time of delivery which will be analyzed for magnesium concentration. Neonates will 
be followed prospectively until NICU discharge or up to 4 months, and numerous 
parameters related to primary and secondary outcomes will be collected via chart review. 
There are no interventions related to this study and there will be no additional sample 
collection or follow-up.  
3.2 Study Population and Sampling  
The source population is pregnant women delivering within the YNHCH, 
Connecticut Children’s Medical Center (CCMC) or Women and Infants Hospital (WIH) 
of Rhode Island. The selection for the study population is derived from mothers given 
antenatal magnesium sulfate who deliver a newborn at less than 32 weeks’ GA. We will 
not limit subjects based on indication for magnesium sulfate therapy e.g. eclampsia 
treatment, seizure prevention in preeclampsia, fetal neuroprotection, tocolysis, or a 
combination. Exclusion criteria consist of neonates born at ≥32 weeks’ GA, outborn 
neonates, neonates who have not been exposed to antenatal magnesium sulfate, neonates 
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with major congenital malformations, and neonates with chromosomal abnormalities. 
Eligibility criteria are summarized in Table 1.  
Because very preterm delivery occurs relatively infrequently, we will utilize 
convenience sampling to select all consented neonates who meet inclusion criteria and 
are free of exclusion criteria.  
Table 1. Eligibility Criteria 
 
Inclusion Criteria Exclusion Criteria  
Neonate born < 32 weeks’ gestation Neonate born ≥32 weeks’ gestation  
Antenatal magnesium sulfate exposure No antenatal magnesium sulfate exposure 
Inborn Outborn  
 Major congenital malformation 
 Chromosomal abnormality 
 
3.3 Recruitment 
 Recruitment will occur at the Level IV NICUs in Connecticut and Rhode Island: 
YNHCH, CCMC, and WIH. We plan to recruit pregnant mothers at risk for preterm 
delivery who are delivering at the three recruitment centers over a twenty-month period. 
Each site will be assigned a research assistant who will provide information about the 
study to clinicians and subjects, enroll eligible patients, and obtain informed consent. As 
delivering mothers can present at any time of day including weekends, we will train the 
fellows at YNHCH and WIH to obtain consent for study participants who present when 
our research assistants are not present. Fellows are involved in all deliveries <32 weeks’ 
gestation and they are present in the hospital 24 hours per day and on weekends. As 
CCMC does not have fellows, we will train the equivalent in-house team leader.  
3.4 Subject Protection and Confidentiality  
 The study will be conducted pending review by each institution’s Institutional 
Review Board (IRB). For example, the Human Investigation Committee of Yale 
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University School of Medicine and the Yale New Haven Health System must approve the 
trial to be conducted at YNHCH. All study personnel will complete Health Insurance 
Portability and Accountability (HIPAA) training and Yale Human Subjects Protection 
training. Study personnel will access all participant electronic medical records (EMRs) on 
university-approved, encrypted, and secure electronic devices. Protected health 
information (PHI) not in electronic form will be stored within a locked cabinet in the 
locked office of the principal investigator, to which only direct research staff will have 
access. All PHI will be disposed of in a secure manner after the study is completed.  
 All mothers will be required to grant written, informed consent in order to 
participate in the study. Consent for the neonate will be given by the mother. Consent is 
necessary as identifiable information will be collected throughout the course of the study. 
A clinical research assistant, trained fellow, or equivalent will explain the consent form 
and participants will have the opportunity to ask questions and discuss concerns prior to 
providing consent. The consent form contains a study description, duration of 
participation, and potential risks and benefits of the study. It will be available in English 
and Spanish with translation to other languages if needed. Interpreter services will be 
utilized as needed for Spanish and other languages. For those who are unable to read, 
informed consent will be obtained after an oral presentation with a third-party present to 
ensure all information is read and accurately represented. An example of the informed 
consent form can be found in Appendix A.  
3.5 Study Variables and Measures  
3.5.1 Independent Variable 
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The independent variable and primary exposure of interest in our proposed study 
is umbilical cord magnesium concentration, which will be operationalized into three 
terciles. The terciles will be created by rank ordering neonates’ magnesium levels and 
then dividing the patients into three groups (low, medium, and high magnesium 
concentrations) with an equal number of participants in each group.  
Samples will be obtained by collecting blood from the umbilical vein into a serum 
separator tube immediately after delivery and freezing within 12 hours at -70°C. Samples 
will then be sent to the laboratory and total serum magnesium will be measured using a 
chemistry analyzer.1 
3.5.2 Primary Dependent Variable 
 
The primary dependent variable is feeding intolerance, which will be assessed by 
the time it takes for a neonate to reach full enteral feed (150 mL/kg/day). Any neonate 
born ≤1250g who reaches full feed past eight days is feeding intolerant per YNHCH’s 
NICU feeding protocol. The longer time it takes for a neonate to reach full feed, the more 
feeding intolerant he or she will be considered. Thus, FI will be operationalized as time to 
an event with the aim of determining incidence rates.  
YNHCH’s feeding protocol will be adopted by all three study centers pending 
minor modifications after conferring with CCMC and WIH. YNHCH’s feeding advance 
regimen can be seen in Table 2.  

































































































































































































































































































3.5.3 Secondary Dependent Variables  
 
There are five secondary outcomes of interest: (1) necrotizing enterocolitis, (2) 
spontaneous intestinal perforation, (3) time to initiation of first feed (not counting buccal 
swabs or oral immunotherapy), (4) time to first stool, and (5) number of abdominal X-
rays in the first 30 days of life. 
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NEC will be assessed with the Modified Bell’s Staging Criteria and will be 
operationalized as a dichotomous variable (yes/no) where yes is classified as stage II or 
III NEC.2 The Modified Bell’s Staging Criteria were adapted from Bell’s original criteria 
in 1986 and remain the most validated way to classify NEC.3 The Modified Bell’s 
Staging Criteria can be found in Table 3.  
SIP will be diagnosed by (1) radiological evidence of perforation in the absence 
of a) clinical features of NEC, b) radiological features of intestinal ischemia e.g. fixed 
dilated bowel loops or pneumatosis intestinalis, or (2) intra-operative surgical report 
and/or histopathology assessment indicating a perforation located in the ileum and on the 
anti-mesenteric border.4,5 SIP will be operationalized as a dichotomous variable (yes/no).  
Secondary outcomes 3-5 are exploratory to further evaluate additional indicators 
of the adverse effect of magnesium on neonatal gastrointestinal function. Time to first 
feed and time to first stool will be operationalized as time to an event in hours with the 
aim of determining incidence rates. Number of X-rays during the first 30 days of life will 
be operationalized as a continuous variable.  
Table 3. Modified Bell’s Staging Criteria for NEC as adapted from 2. 
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3.5.4 Potential Confounding and Explanatory Variables  
 
Potential covariates which include maternal, perinatal, and neonatal baseline 
characteristics as identified in the literature review will be compared between the three 
study groups by univariate analysis. Statistically significant variables will be adjusted for 
in regression models to determine if they are significant covariates for each outcome. A 
summary of baseline characteristics and how we plan to test them on univariate analysis 
can be found in Table 4. We will control for the confounder of GA at delivery by 
stratifying data into neonates born <25 weeks, 25-27 and 6/7 weeks, and 28-31 and 6/7 
weeks. Birth weight and additional covariates identified will be analyzed with subgroup 
analyses.  












    
  Age (years) mean ± SD mean ± SD mean ± SD ANOVA 
  Body mass index mean ± SD mean ± SD mean ± SD ANOVA 
  Race:     
     White n (%) n (%) n (%) Chi-square 
     Black n (%) n (%) n (%) Chi-square 
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     Other n (%) n (%) n (%) Chi-square 
Perinatal 
Characteristics 
    
  Magnesium sulfate  
  total dose (g) 
mean ± SD mean ± SD mean ± SD ANOVA 
  Magnesium sulfate 
  total duration (hours) 
mean ± SD mean ± SD mean ± SD ANOVA 
  Length of rupture of  
  membranes (hours) 
mean ± SD mean ± SD mean ± SD ANOVA 
  Indication for  
  magnesium sulfate  
    
     Maternal  
     preeclampsia or  
     eclampsia 
n (%) n (%) n (%) Chi-square 
     Fetal  
     neuroprotection 
n (%) n (%) n (%) Chi-square 
     Tocolysis  n (%) n (%) n (%) Chi-square 
  Hospital of delivery      
     YNHCH n (%) n (%) n (%) Chi-square 
     WIH n (%) n (%) n (%) Chi-square 
     CCMC n (%) n (%) n (%) Chi-square 
  Cesarean delivery n (%) n (%) n (%) Chi-square 
  Antenatal steroids n (%) n (%) n (%) Chi-square 
  Multiple gestation n (%) n (%) n (%) Chi-square 
Neonatal 
Characteristics 
    
  Umbilical Cord Mg 
  Concentration  
  (mg/dL) 
mean ± SD mean ± SD mean ± SD ANOVA 
  GA (weeks) mean ± SD mean ± SD mean ± SD ANOVA 
  Birth weight (g) mean ± SD mean ± SD mean ± SD ANOVA 
  Male sex n (%) n (%) n (%) Chi-square 
  SGA n (%) n (%) n (%) Chi-square 
  Apgar score <7 at 5  
  minutes 
n (%) n (%) n (%) Chi-square 
  Human milk feeding      
     All n (%) n (%) n (%) Chi-square 
     Partial n (%) n (%) n (%) Chi-square 
     None n (%) n (%) n (%) Chi-square 
  Sepsis n (%) n (%) n (%) Chi-square 
  Postnatal steroids  n (%) n (%) n (%) Chi-square 
  Postnatal NSAID for 
  treatment of PDA 
n (%) n (%) n (%) Chi-square 
  Postnatal  
  Indomethacin for IVH 
n (%) n (%) n (%) Chi-square 
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  prophylaxis  
 
3.6 Additional Methodology Considerations   
 Maternal magnesium sulfate regimen will be based off protocols at respective 
institutions. At YNHCH, women who receive magnesium sulfate but do not deliver 
within 12 hours are retreated. As outlined in the literature review, we expect increasing 
total dose of magnesium sulfate to be associated with increased neonatal cord blood 
magnesium concentration. As this is on the causal pathway, it is not considered to be a 
covariate. Total dose of magnesium sulfate will be calculated by adding the loading dose 
to the product of the infusion dose and duration.  
3.7 Blinding of Exposure and Outcome  
 Other than the fellows or equivalents obtaining consent, NICU teams including 
attendings and nursing staff will be unaware of a neonate’s umbilical cord magnesium 
concentration and thus will not know neonatal groupings. They will also be unaware of 
the outcomes of interest to avoid hypervigilance leading to a change in management. 
Additionally, there will be minimal contact between study investigators and clinical 
teams to prevent influencing care.  
3.8 Data Collection  
 After consent is obtained, mothers will fill out an intake survey which will assess 
maternal demographics (age, race, parity, body mass index during the first visit for the 
present pregnancy), comorbidities, serum creatinine, and pregnancy complications. 
Surveys will be administered by a research assistant during the initial recruitment of 
pregnant mothers. Any information unknown to the mother will be elicited from the 
maternal EMR. An example of the intake survey can be found in Appendix B.  
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 Neonatal baseline characteristics and outcome data will be obtained from neonatal 
EMRs and recorded into a data collection sheet. An example of the data collection sheet 
can be found in Appendix C. For completeness, we will extract data at the time of 
delivery, at one week, at two weeks, at one month, and at discharge from the NICU or 
four months after delivery (whichever comes first). If necessary, study personnel can 
clarify clinical questions regarding outcome data with the care team in near real-time. We 
have chosen to obtain outcome data via chart review because we believe that having 
study personnel round on patients to collect data regarding outcomes could influence 
care. Adherence is not applicable to our study as there are no interventions after initial 
umbilical cord sample is drawn.  
3.9 Sample Size Calculation  
 The main goal of the proposed study is to test the two-sided null hypothesis that 
there is no difference in incidence rate of FI (time to full enteral feed defined as 150 
mL/kg/day) in the low tercile as compared to medium and high terciles of magnesium 
concentration from 0-4 months among very preterm neonates. Our calculation was 
performed using the Power and Precision 4 Software (Biostat, Inc) under the assumption 
that a log-rank test could be used, as FI is operationalized as time to an event.  
Our sample size is limited by the number of inborn neonates <32 weeks’ GA at 
our three study centers so we needed to work backwards from our fixed sample size to 
identify the hazard rate we would be powered to detect. Per data collected by Yale New 
Haven Health, approximately 130 neonates <32 weeks’ gestation are born each year at 
Yale New Haven Hospital. Per data sent by respective faculties, there were 156 neonates 
<32 weeks’ gestation inborn at WIH and 75 neonates <32 weeks’ gestation inborn at 
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CCMC in 2018. In total, we estimate that approximately 601 very preterm neonates will 
be inborn at our study centers during the twenty-month period we have designated for 
subject accrual. With the help of an obstetric fellow at Yale, we estimate that 90%, or 541 
neonates, should receive antenatal magnesium sulfate and thus be available for 
recruitment to our study. Of those available, we estimate a 90% success rate of 
recruitment secondary to the low risk and lack of intervention associated with our study. 
Therefore, our feasible starting sample size is 486 neonates.  
From our starting sample size, we anticipate the need to account for mortality and 
to control for covariates. To account for mortality, we will only include neonates that 
survive past six weeks in our data analyses as this is long enough to be at risk for our 
primary and secondary outcomes. We estimate 10% mortality of our study population 
prior to six weeks based on data from 2013-2018 at YNHCH revealing 88% average 
survival to discharge (assuming some of these deaths will occur past 6 weeks). To control 
for four covariates, we will require ten extra neonates per group per covariate (totaling 
120 neonates to control for confounding). Thus, we will start with 162 neonates per 
tercile for our crude analysis and 122 neonates per tercile for our adjusted analysis, 
noting a drop rate of 0.10 due to mortality prior to six weeks. For the adjusted analysis, 
we will be powered to detect a hazard rate as small as 0.68 between the low and medium 
terciles for a two-sided test with criterion for significance (α) = 0.05 and power of 81%. 
This is based on the median survival published by a similarly designed study by 
Narasimhulu et al.6 The total calculation can be found in Appendix D.  
There is no additional follow-up or data collection other than chart review after 
initial umbilical cord sample is taken. In addition, neonates born at <32 weeks’ of 
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gestation are infrequently transferred out of the Level IV NICUs where we will conduct 
the study and, if so, are usually transferred to a within-network hospital using the same 
EMR as the Level IV NICU so data can continue to be collected. We therefore do not 
need to correct for loss to follow-up. If the sample size requirement has been met prior to 
twenty months, additional subjects may continue to be recruited to strengthen the study 
analysis.   
3.10 Statistical Analysis 
 First, baseline maternal, perinatal, and neonatal characteristics among the three 
study groups (low, medium, high terciles of umbilical cord magnesium concentration) 
will be compared using chi-square or Fisher’s exact test for categorical variables and 
analysis of variance (ANOVA) test for continuous variables, as appropriate. Continuous 
endpoints will be expressed as medians and IQRs or as means +/- SD. Categorical 
endpoints will be summarized as frequencies and proportions.  
Second, we will test our unadjusted main hypothesis by creating Kaplan-Meier 
survival curves and using log-rank tests to perform time to full enteral feed analyses for 
each group. For our adjusted analysis, we will stratify based on gestational age with a 
stratified Cox model. We will also use Cox proportional-hazards regressions to identify 
and control for additional covariates.  
Third, we will analyze secondary outcomes. For NEC and SIP, we will compare 
incidence proportions of dichotomous outcomes with chi-square tests for our unadjusted 
analysis and multivariate adjustment through multiple logistic regression to control for 
confounders in our adjusted analysis. Time to first feed and time to first stool will be 
analyzed using the Kaplan-Meier method and log-rank test followed by Cox 
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proportional-hazards regression model to control for confounding. For number of X-rays 
in one month we will compare means between the three terciles with ANOVA. We will 
perform this particular analysis after excluding neonates who develop NEC and SIP, as 
they will typically receive many X-rays which would obscure the results regarding 
feeding tolerance in neonates without NEC or SIP. A p value of <0.05 will be considered 
statistically significant. All analyses will be performed using SPSS software v22.0 (SPSS 
Inc., Chicago, IL).   
3.11 Timeline and Resources  
 Pending IRB approval, we will recruit pregnant women at imminent risk for 
preterm delivery over twenty months. All mothers included in the study must have been 
administered antenatal magnesium sulfate and must deliver a neonate at <32 weeks’ 
gestation within the first twenty months of the study. From the point of delivery, we will 
follow each neonate forward until discharge from the NICU or, if not yet discharged, for 
a total of four months. The study will be completed within two years. We will then 
interpret results and report our findings. 
Proposed study personnel include:  
• One principal investigator and one co-investigator to oversee all operations: Dr. 
Steven Peterec and Giavanna Chirico, PA-SII 
• Three research assistants, one for each study center, trained for recruitment, 
obtaining informed consent, and intake survey delivery 
• YNHCH and WIH neonatal-perinatal fellows and CCMC equivalent, trained for 
recruitment, obtaining informed consent, and intake survey delivery throughout 
the night and on weekends (when research assistants are not available) 
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• Three collaborating maternal-fetal medicine fellows, or equivalent, one at each 
center, to coordinate and oversee cord blood collection and temporary storage  
• One physician associate student, Giavanna Chirico, for chart review, data 
organization, and writing 
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CHAPTER 4: CONCLUSION  
4.1 Advantages  
 Our study has several major strengths. First, the prospective design allows us to 
analyze a diverse group of high-risk neonates in a real-world setting and to identify 
outcomes as they occur in real-time. Although an RCT is the ideal study design to 
determine causation, antenatal magnesium sulfate is the standard of care for fetal 
neuroprotection in our study population so randomizing women to not receive 
magnesium would be unethical.  However, our study design allows us to evaluate the 
effect of magnesium exposure without randomization by dividing neonates into terciles 
based on magnesium sulfate level in cord blood.  
Next, NICU teams do not know the magnesium concentration of each neonate or 
the specific parameters we are interested in related to our outcomes, which minimizes 
information bias and improves the internal validity of our study. We have further 
strengthened internal validity by including an extra 120 neonates solely to control for 
confounding variables. 
 Our study design is both feasible and ethical. By using umbilical cord blood rather 
than neonatal blood drawn after delivery, we will not expose the neonate to additional 
risks such as phlebotomy blood loss which could result in iatrogenic anemia and the need 
for blood transfusions, as well as pain or risk of infection from drawing a blood sample.1,2 
Additionally, by only drawing a sample of umbilical cord blood at the time of delivery 
and not requiring any other blood samples or follow-up appointments, we minimize loss 
to follow-up. Other than privacy, there is no risk of participation to the neonate, and thus 
negligible ethical concerns. 
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Finally, we have improved the external validity and generalizability of our study 
by utilizing multiple study centers. We also include the use of antenatal magnesium 
sulfate for any indication and women at risk for preterm birth for any indication which 
further increases the generalizability of our study and minimizes selection bias.  
4.2 Limitations  
Despite significant attention to study methodology, we acknowledge that this 
study has potential limitations. Our sample size is limited as there are only a certain 
number of neonates born <32 weeks’ gestation at our three study centers. Having a larger 
sample size would increase our power to detect an association and would allow us to 
control for more covariates. Although having multiple study centers increases our sample 
size and generalizability, it introduces the potential for information bias secondary to 
variations in obstetric and neonatal care across study centers. In order to minimize the 
aforementioned variability, all study centers will adopt YNHCH’s feeding protocol after 
conferring and making any minor modifications that may be needed.  
We foresee two problems that could occur related to our exposure of interest and 
primary outcome. First, we may obtain a narrow range of umbilical cord magnesium 
concentrations. If this is the case, our low, medium, and high terciles will not be 
significantly different from one another, and it will be unlikely that we will see a 
difference in outcomes even if an association between elevated magnesium and our 
outcomes does exist. Second, our primary outcome, FI, has no definitive diagnostic test. 
We chose time to full enteral feed as our measure of FI as it will capture any delay in 
feeding due to signs and symptoms of FI; however, there are events that delay feeding for 
reasons unrelated to FI. For example, YNHCH’s feeding protocol states to maintain or 
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reduce feeding volumes when a neonate is found to have a hemodynamically significant 
PDA and is treated with Indomethacin. In this scenario, our neonate may appear to be 
“feeding intolerant” when that may not be the case. We hope that should this scenario 
arise it will occur evenly in the three groups and effectively cancel the impact on our 
primary outcome.  
Lastly, we recognize that the feeding protocol that our study centers will adopt 
follows advancement of enteral feed volumes by 24 mL/kg/day which will impact the 
time it takes to reach full feed.3 As all subjects will be following the same feeding 
regimen, conclusions regarding an association between magnesium and time to full feed 
will still be accurate, but the exact number of days to reach full feed should not be used to 
estimate effect size in future studies where centers could have slower or faster 
advancement of enteral feeds.   
4.3 Clinical Significance  
As all neonates born very preterm should have antenatal magnesium sulfate 
exposure, the safety of this treatment is paramount. In current practice, administration of 
maternal magnesium sulfate is interrupted when signs of maternal magnesium toxicity, 
such as depressed reflexes, are present on exam or when maternal magnesium 
concentration is above the recommended therapeutic range.4 We practice under the 
assumption that maternal clinical symptoms or magnesium levels can be monitored to 
assure fetal clinical safety because it is not reasonable to obtain fetal magnesium levels 
and it is not standard care to obtain neonatal magnesium levels. A fetus can have a 
magnesium concentration outside of a safe range as his or her mother continues to receive 
a magnesium sulfate infusion. Since the gastrointestinal outcomes discussed are already 
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known to be associated with prematurity, this can lead to the dangerous assumption that 
neonates born to mothers without overt signs of magnesium toxicity are developing 
complications due solely to their prematurity and not in part to their elevated magnesium 
levels as a result of their magnesium exposure.  
If this study identifies an association between high cord magnesium 
concentrations and feeding intolerance, then neonatal cord or early postnatal magnesium 
levels could be used to identify neonates at increased risk for feeding intolerance. By 
increasing a clinician’s index of suspicion, there would be opportunity for better 
monitoring, earlier recognition and interventions to decrease the negative consequences 
of FI. Additionally, knowing a neonate had magnesium exposure may allow a clinician to 
avoid unnecessary testing in the setting of feeding intolerance when the neonate 
otherwise appears well. If this study identifies an association between high cord 
magnesium concentrations and NEC or SIP, then neonatal cord or early postnatal 
magnesium levels could be used to identify neonates at increased risk for these 
devastating neonatal morbidities and possibly allow their prevention through 
modification of care practice. Finally, clarifying the relationship between high cord 
magnesium concentrations and adverse gastrointestinal outcomes could elucidate whether 
changes need to be made to the maternal magnesium sulfate treatment regimen to prevent 
elevated neonatal magnesium concentrations in the first place.  
Alternatively, identifying that there is no association between elevated 
magnesium and FI, NEC, or SIP could be equally as beneficial. Our study, which avoids 
some of the limitations of existing studies, could demonstrate that magnesium level is not 
associated with increased risk for these gastrointestinal outcomes. Feeding problems in a 
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newborn exposed to magnesium therapy would not erroneously be attributed to 
magnesium level, making it less likely that other underlying pathology is missed. It 
would also increase our confidence in the safety of antenatal magnesium sulfate for very 
preterm neonates.  
 We recognize that observational studies alone cannot be the basis for changing 
clinical practice. Nevertheless, if we document an association between elevated 
magnesium levels and neonatal gastrointestinal problems, it could help to create 
opportunities for early intervention and mitigation of the effects of FI, NEC, and SIP in 
very preterm neonates. If no association is identified, our study would benefit the 
scientific community by clarifying data that have long been unclear or conflicting. Either 
result will reveal important information about the safety, or lack thereof, of antenatal 
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Appendix A: Parental Consent Form 
310 PR. 1: Informed Consent in Research Involving Children 
 
Title of Study: Magnesium Exposure in Very Preterm Neonates and Adverse 
Gastrointestinal Outcomes  
Principal Investigator: Steven Peterec, M.D.  
Affiliation: Yale University School of Medicine and Yale New Haven Health System  
 
Invitation to Participate and Study Purpose:  
 We are inviting you and your child to participate in a research study designed to 
look at the relationship between magnesium concentration in the blood and 
gastrointestinal outcomes in preterm infants. You and your child have been asked to 
participate because he/she will be born preterm, you are being treated with magnesium, 
and this will result in your child being exposed to antenatal magnesium sulfate. We plan 
to study over 500 newborns born within Yale New Haven Children’s Hospital, 
Connecticut Children’s Medical Center, and Women and Infants Hospital of Rhode 
Island to study this question. Newborns will be followed until discharge from the NICU 
or up until four months of their life.  
 In order to decide whether you wish yourself and your child to be a part of this 
research study, please read this form which provides detailed information about the study. 
Next a member of our research team will discuss the purpose, procedures, risks, and 
benefits of the study with you so that you can make an informed decision. Once you are 
confident that you understand the study, you will be asked if you wish for yourself and 
your child to participate; if so, you will be asked to sign this form.  
 
Description of Study and Procedures Used:  
• We will ask you to fill out a survey which will include a number of questions 
about your medical, social, and demographic history to get an accurate picture of 
your baby’s exposures and environment. If you are unable to answer any 
questions, we will review your medical record to see if it provides an answer. 
• We will draw a sample of blood from the umbilical vein during your delivery 
which will be analyzed to determine the concentration of magnesium. The 
umbilical vein is a blood vessel in the umbilical cord. When your baby is 
delivered the cord is clamped and cut; we will obtain the blood from the part of 
the umbilical cord that is attached to the placenta and is usually discarded after 
delivery. We will not draw the blood from the part of the cord still attached to 
your baby after delivery, nor from anywhere else from your baby.  
• We will then review your baby’s medical record at delivery, 1 week, 2 weeks, 1 
month, and either at the time of discharge from the Newborn Intensive Care Unit 
or at 4 months to determine baseline characteristics of your child as well as 
parameters relating to the gastrointestinal outcomes we are analyzing, particularly 
related to how well your baby tolerates feeds and whether your baby has any 
problems associated with the intestines.  
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• The only procedure we will be performing is drawing the blood sample at the time 
of delivery. There will be no further time commitment or procedures for you or 
your child to partake in.  
 
You will be told of any findings that develop during the course of your child’s 
participation in this study that may affect your willingness to continue to participate.  
 
Risks and Inconveniences  
There are no physical risks associated with this study. Although we will make 
every effort to safeguard you and your child’s information (as we will describe below), 
there is the risk of loss of confidentiality.  
 
Expected Benefits  
 This study aims to clarify whether elevated magnesium concentration in the 
preterm infant, as a result of maternal magnesium sulfate treatment, is associated with 
feeding intolerance and other gastrointestinal outcomes. While you and your baby are 
unlikely to receive any direct benefit as a result of this research, you may help to advance 
the medical community’s understanding of the risks associated with elevated magnesium 
concentration and improve the care of future mothers and their babies.  
 
Economic Considerations 
There will be no costs associated with you or your child’s participation in this 
research study. There will also be no paid reward for participation in this study. 
 
Confidentiality of Information 
 Any identifiable information that is obtained throughout this study will remain 
confidential and will only be disclosed as required by United States, Connecticut, or 
Rhode Island State law. Only the researchers involved in this study and those responsible 
for research oversight (such as representatives from the Yale University Human Research 
Protection Program and members of the Institutional Review Boards at the hospital where 
you are delivering your baby), will have access to any identifiable information that we 
collect. These individuals are required to keep all information confidential as well. When 
the results of the research are published or discussed, no information will be included that 
would reveal your child’s identity unless your specific permission for this activity is 
obtained.  
 We will protect your information by only accessing electronic medical records on 
university-approved, encrypted, and secure electronic devices. All healthcare providers 
and research staff are subject to the Health Insurance Portability and Accountability Act 
(HIPAA) and thus are required to protect the privacy of your information. Our data 
collection sheets will be stored within a locked cabinet within the locked office of the 
principal investigator. Information related to you and your baby and the blood sample 
collected as part of the research will not be used or distributed for future research studies.  
 
Research Subjects’ Rights 
You are free to choose not to have yourself and your child participate and doing 
so will not result in penalty or loss of benefits that you or your baby is otherwise entitled 
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to (such as your child’s health care outside the study). If you do choose to allow yourself 
and your child to participate in this study, you may withdraw yourself and your child 
from the study at any time with no penalty or loss of benefits. You can do so by calling or 
sending written notice to the Principal Investigator, Dr. Steven Peterec, at 1 Park Street 
New Haven, CT, 06504. When you withdraw your permission, no new personal health 
information will be gathered after that date. Information that has already been gathered 
may still be used until the end of the research study to ensure the integrity of the study 
and/or study oversight. Refusing to participate or withdrawing from the study will not 
have any effect on you or your child’s relationship with your own doctors or within the 
Yale New Haven Health System, Connecticut Children’s Medical Center, or Women and 
Infants Hospital of Rhode Island. 
 
Questions 
 We have used technical terms in this form. Please feel free to ask about anything 
you do not understand. Consider your options as long as you feel necessary before 
making a decision.  
 
Authorization  
 I have read (or someone has read to me) this form, and I have decided to allow 
myself and my child to participate in the project described above. Its general purposes, 
the details of mine and my child’s involvement, the possible risks and inconveniences, 
and the possible benefits have been explained to my satisfaction.  
By signing this form, I give permission to the researches to use information about 
myself and my child for the purposes described in this form. By refusing to give 
permission, I understand that I or my child will not be able to participate in this research 
study. My signature also indicates that I have received a copy of this permission form.  
 
Name of Child: _____________________________ 
 
Signature of Parent: _________________________       Date: ____________________ 
 
Name of Person Obtaining Consent (Print): ________________________________ 
 
Signature of Person Obtaining Consent: _______________________Date:____________ 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principle Investigator at his office. [Dr. Peterec at 203-688-2320] 
 
If after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919. 
 
If you have questions about your rights as a research participant, or you have complaints 
about this research, you can contact the Yale Institutional Review Boards at 203-785-
4688 or email hrpp@yale.edu. 
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Appendix B: Maternal Intake Survey  
 
Name: _________________________  Date: ______________________ 
Medical Record Number: ________________ Hospital: _____________________ 




Serum Creatinine: _______________ 
Past Medical History:____________________________________________________ 
 
_______________________________________________________________________  
Have you ever been diagnosed with elevated blood pressure or hypertension? 
 Have you ever been diagnosed with diabetes mellitus? 
Have you had any of the following with your current pregnancy?  
 Gestational diabetes? 
 Preeclampsia? 
 Eclampsia? 
 Multiple gestation (twins or more)? 
 Other?____________________________________________________________ 
Past Obstetric History: 
 What number pregnancy is this? 
 How many living children do you have? 
 Have you had any complications with prior pregnancies? 
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Appendix C: Data Collection Sheet  
Name:___________________________ MRN: _________________________ 
Name of mother: _____________________  Mother MRN:___________________ 
Date of Birth:____________________ Hospital: __________________________ 
Gestational age at delivery: _______________ 
Birth weight: __________________________ 
Umbilical cord magnesium concentration: _________________ 
Perinatal Factors: 
Antenatal Magnesium Sulfate Exposure: 
  Total dose (g): _______________ 
  Total duration (hours): _______________ 
  Indication for magnesium sulfate: _______________ 
 Antenatal steroids (y/n): _______________ 
 Length of rupture of membranes (hours): _______________ 
 Mode of delivery (vaginal, cesarean): _______________ 
 Multiple or single gestation: _______________ 
Neonatal and Postnatal Factors:  
Sex: _______________  
SGA (y/n): _______________ 
 Apgar score at 5-minutes: _______________ 
 Human milk feeds (all, partial, none): _______________ 
Postnatal Indomethacin for IVH prophylaxis (y/n): _______________ 
Postnatal NSAID treatment for PDA (y/n): _______________ 
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Postnatal steroids 
Hydrocortisone (y/n): _______________ 
Dexamethasone (y/n): _________________ 
 Sepsis (y/n): _______________ 
Outcomes:  
 Time to full enteral feed (150 mL/kg/day): _______________ 
Necrotizing enterocolitis stage II or III (yes/no): _______________ 
Spontaneous intestinal perforation (yes/no): _______________ 
Time to first feed (hours): _______________ 
 Time to first stool (hours): _______________ 
 Number of abdominal X-rays in first 30 days of life: _______________ 
 
*Data collection terminates in the cases of neonatal death, discharge from the NICU, or 4 
months after delivery.  
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Appendix D: Sample Size Calculation  
 



























Tercile   
20 4 24 6.1 122 1.61 0.43 0.00 0.10 
Middle 
Tercile 
   6.1 122 1.10 0.63 0.00  
    12.2 244 0.68    
Alpha = 0.05, Tails = 2    Power = 81% 
 
 
 In this chart, we calculate that we are powered to detect a hazard rate of 0.68 for 
our primary outcome between the low and middle tercile groups. This calculation was 
made using a two-tailed test with an alpha = 0.05 and 122 neonates per group, the fixed 
number of neonates we have available per tercile after controlling for confounding. Data 
for median survival in months between the two groups were estimated from Narasimhulu 
et al., where neonates in the low magnesium group took a median of 13 days to reach full 
feed and neonates in the medium magnesium group took a median of 18 days to reach 
full feed.1 Drop rate is 0.10 as we estimate 10% mortality for our study population.  
Interval survival was estimated to be 0 as we expect all surviving subjects to eventually 
reach full enteral feed in the allotted 4 months. Including the high tercile group, which 
was not required for this calculation, we will have 366 total subjects for our adjusted 
analysis. We have accounted for 120 additional neonates to control for confounding, so 
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